Shanghai BioTroy Therapeutics

BioTroy Therapeutics is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of next-generation small molecule therapies for undruggable oncology targets. The company focuses heavily on the RAS signaling pathway, utilizing its proprietary Troy-Horse platform to design highly selective inhibitors for specific KRAS mutations. Its lead program, BT-101, is a potent KRAS G12D inhibitor currently undergoing Phase 1 clinical trials for patients with advanced solid tumors. BioTroy's pipeline also includes candidates targeting KRAS G12V and SOS1, aiming to address significant unmet needs in pancreatic, colorectal, and lung cancers. The company is led by industry veterans with extensive experience in RAS drug discovery and is supported by top-tier life science investors.